Abstract:Purpose: To investigate the radiolabeling of E-B5, a monoclonal antibody against Pro-GastrinReleasing Peptide(31-98)by Iodine and study the stability and immunoreactivity of I-E-B5. To determine the in vivo biodistribution of I-E-B5 in normal Kunming mouse and small cell lung cancerbearing nude mouse models(SCLC mouse model) to study the pharmacokinetics of the I-E-B5 in vivo. Characterize the radioimmunoimaging effect and the best imaging time of I-E-B5 in different types of tumors. Methods: I-E-B5 was labeled by chloramine–T method. The labeling efficiency and radiochemical purity were determined by thin-layer chromatography. The I-E-B5 was incubated at 37°C water bath by itself or mixed with normal human serum, the radiochemical purity was then checked at different time points to determine its stability, and the immunoreactivity was determined by cell binding assays.I-E-B5 was injected into the tail veins of the normal Kunming mice which were sacrificed at different time points after injection, and the blood and representative tissues were collected immediately, and the %ID/g (percentage injected dose per gram of tissue) and pharmacokinetic parameters were calculated at various time points. Similarly, T/NT (tumor to non-tumor radioacticity ratio) at various time points were calculated after injection of I-E-B5 into the SCLC model. Mouse models bearing small cell lung cancer, lung adenocarcinoma, colon cancer were utilized to study the radioimmunoimaging effect of I-E-B5, and calculate the T/B ratio (tumor volume to the corresponding location at the other side). Results: I-E-B5 labeling rate was 90.8%, radiochemical purity was 99.28%, and radioactivity was 2.69 MBq/ug. The radiochemical purity of I-E-B5 was 90% after 6 hr at 37°C water bath, and remained at more than 70% after 24 hrs. The radiochemical purity was over 68.1% after 24 hrs mixing with normal human serum. The immunobinding rate of I-E-B5 to NCI-H446 (SCLC cell lines) and A549 (lung adenocarcinoma cell lines) was 71.6%, and 33.2%, respectively. The pharmacokinetics of I-E-B5 is consistent with a two-compartment model with first-order absorption. It was primarily metabolized via liver and kidney. The serum clearance rate is relatively fast. The %ID/g of I-E-B5 in xenografts was dramatically increased to a level much higher than other tissues 48 hrs after injection, reached plateau at 72 hr, and the T/NT ratio was also gradually increased with time. Prominent uptake of I-E-B5 in xenografts of SCLC in nude mice was observed after 24 hrs of injection. The radioactivity in the xenografts was gradually increased with time, and reached the peak at 72 and 96 hr. Xenografts of colon cancer showed similar results as that of SCLC although at a lower level. No observable accumulation was seen in the xenografts of lung adenocarcinoma. The T/B ratio in xenografts of SCLC was consistently higher than in colon cancer at all the time points, and both were significantly higher than that of lung adenocarcinoma which remained stable during the observation duration. Conclusion: The labeling rate and radiochemical purity of I-E-B5 were high and stable both in vivo and vitro. The labeled E-B5 kept its immunologic activity. I-E-B5 selectively accumulated at tumors expressing proGRP, and could effectively target SCLC, therefore is a promising radioimmunoimaging reagent for SCLC.

[Radiolabelling of a lung cancer-targeting small molecule polypeptide with (131)I and its radioactivity distribution in normal rabbits]

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

Evaluation of Tumor Vascular Targeting Agents Labelled with 131I in Imaging of Tumor

SPECT Imaging of Neuropilin Receptor Type-1 Expression with 131I-Labeled Monoclonal Antibody.

Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed α v β 3 Integrin Receptors in Non-Small-Cell Lung Cancer

Experimental study of pharmacokinetics and radioimmunoimaging of 131 Iodine-labeled monoclonal antibody E-B 5 against Pro-Gastrin-Releasing Peptide ( 31-98 )

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

Iodine-124 Labeled Gold Nanoclusters for Positron Emission Tomography Imaging in Lung Cancer Model.

Biodistribution and Gamma Imaging of 99Tcm-Arginine-glutamate-threonine in Human Lung Cancer Xenografts

Preliminary radioimmunoimaging and biodistribution of ¹³¹iodine-labeled single-chain antibody fragment against progastrin-releasing peptide(₃₁₋₉₈) in small cell lung cancer xenografts.

[Radio-labeling of T7 peptide with 99mTc and its biodistribution in nude mice bearing non-small cell lung cancer].

Radiolabeling, Characteristics and NanoSPECT/CT Imaging of 188Re-cetuximab in NCI-H292 Human Lung Cancer Xenografts

Kit-like 18F-labeling of RGD-19F-arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging.

Validation study of 131I-RRL: Assessment of biodistribution, SPECT imaging and radiation dosimetry in mice

Preparation of 68Ga-Dota-cngr and Its Application in Imaging of the Nude Mice Bearing Human Lung Cancer

A novel radioiodinated peptide of arginine-arginine-leucine(RRL)for biodistribution and tumor angiogenic endothelium imaging

A Novel Tc-99m-Labeled Molecular Probe For Tumor Angiogenesis Imaging In Hepatoma Xenografts Model: A Pilot Study

Biodistribution Characteristics and SPECT Imaging Of99mtc-Ret And99mtc-Reg in Human Lung Cancer Xenografts

Single Step 18F-Labeling of Dimeric Cyclorgd for Functional PET Imaging of Tumors in Mice.

Synthesis and biodistribution of 99Tcm-Cetuximab antibody for lung tumor targeted molecular imaging

Preparation of 68Ga-DOTA-cRGD and its utility for lung adenocarcinoma bearing nude mice imaging